Mylan CEO Claims EpiPens Aren’t As Profitable As Everyone Thinks
(By Alison Kodjak for NPR) The drug company that makes the EpiPen says it isn’t nearly as profitable as many
Read More
Part D/Prescription Drugs
How Much Has Medicare Spent on the EpiPen Since 2007?
(By Juiette Cubanski, Tricia Neuman, and Anthony Damico for Kaiser Family Foundation) The latest example of high and rising prescription
Read MoreVeterans Courted In California’s Ballot Fight Over Curbing Drug Prices
(By Pauline Bartolone for California Healthline) Once a month at the Veterans of Foreign Wars building in Sacramento, a couple
Read MoreCalifornia governor decries ‘predatory’ pricing as he signs law to make EpiPen available
(By Ed Silverman for STAT) For all intents and purposes, California Governor Jerry Brown held his nose Friday as he
Read MoreSarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
(By Ed Silverman for STAT) The newly approved1 Sarepta Therapeutics drug for Duchenne muscular dystrophy2 will cost about $300,000 a
Read MoreAs profitable fentanyl industry expands in China, US negotiates to halt the deadly trade
(By Kathleen McLaughlin for STAT) BEIJING — Top American and Chinese enforcement officials are negotiating how to fight the rampant
Read MoreNilotinib: Is it the Cure for Lewy Body Dementia?
Don Carano believes there is a cure for Lewy Body Dementia but medical experts disagree and say more research is
Read MoreFDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
(By Ed Silverman for STAT) he Food and Drug Administration on Monday approved1 a controversial drug to treat Duchenne muscular
Read MoreGlobal leaders are set to put superbugs on the world stage
(Helen Branswell for STAT) Heads of state from around the globe will gather this week to try to address a
Read MoreCancer Immunotherapy At A Crossroads
(By Bret Stetka for NPR) It was in 1909 that Nobel Prize-winning German physician Paul Ehrlich proposed the idea that
Read More